MetaCap

Immuron (IMRN) vs MetaVia (MTVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immuron is the larger company by market cap ($7.3 million vs $6.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMRN-17.45%MTVA-30.82%
+12%-10%-33%
Oct 7, 20261 yearNov 20, 2026
IMRN-16.69%MTVA-28.37%
+3%-13%-30%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMRN versus MTVA key metrics
MetricIMRNMTVA
Share price$0.8998$1.01
Market cap$7.26M$6.81M
1-day change+5.80%-7.34%
EPS (TTM)$-0.34$-2.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-12.97M
52-week high$1.99$13.42
52-week low$0.677$0.966
Distance from 52-week high-54.78%-92.47%
Analyst consensusnonenone
Avg. price target upside+332.32%+1813.86%
Average volume2.06M113.44K
Shares outstanding8.07M6.74M
Employees78
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Immuron

IMRN stock →

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About MetaVia

MTVA stock →

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

IMRN vs MTVA FAQ

Which is bigger, Immuron or MetaVia?

Immuron (IMRN) is larger, with a market capitalization of $7.26M compared with $6.81M for MetaVia (MTVA).

Are Immuron and MetaVia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons